Actuate Therapeutics Inc (ACTU) Stock

Actuate Therapeutics Inc (ACTU) is a Healthcare stock trading at $2.10 (as of 2026-06-18), with a market capitalization of $96.23M and a trailing P/E of -2.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, including Elraglusib Injection, a glycogen synthase kinase-3 inhibitor being studied for metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for Ewing sarcoma, metastatic melanoma, and colorectal cancer.

Valuation — source: SEC EDGAR (first-party)
Price	$2.10
Market Cap	$96.23M
P/E Ratio	-2.1
Price / Book	12.77
Price / Sales	151.34
DCF Value (model)	$-13.24
DCF Upside vs Price	-730.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$287710.00
Net Margin	-7725.8%
Return on Equity	-569.1%
Current Ratio	1.80
Revenue Growth (YoY)	29.4%
EPS Growth (YoY)	-67.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-15.12 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-109.9%
vs Industry	-112.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BIOS Capital Management, LP ($27.54M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daniel Schmitt
Employees	10
Country	US
IPO Date	2024-08-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.